Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on IDT Australia.
RELATED STOCKHEAD STORIES
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX crushed with all 11 sectors deep in the red, but there’s some good news from China
Health & Biotech
ASX Health Stocks: Island Pharma releases data on dengue fever drug, IDT signs $3m+ deal with Sanofi
Health & Biotech
Weed Week: Cannabis stocks down almost 20pc in 2023, but here’s why they could rebound by Q2 2024
Health & Biotech
Weed Week: Cannabis boom a ‘matter of when, not if’; and NSW to allow residents to grow pot
Health & Biotech
ASX Health Winners: Biotechs up 10pc in November, and Janus Henderson’s prediction for 2024
Health & Biotech
Check Up: Imugene’s oncolytic virus VAXINIA granted FDA’s Fast Track, but how effective is this novel therapy?
Health & Biotech
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Health & Biotech
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
News
In Case You Missed It: A strategic superannuation partnership takes the lead today
Health & Biotech
ASX Health Stocks: IDT on strong growth trajectory, Paradigm smashed 30pc on cap raise
News
Top 10 at 10: WA1 scales new heights, REZ hits a shallow nickel orebody in the making
Health & Biotech
Weed Week: New studies confirm cannabis alleviates cancer pain, cuts need for opioids, and improves sleep
Health & Biotech
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales
Health & Biotech
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
Health & Biotech
ASX Biotech Stocks: Noxopharm eyes new mRNA product with market forecast to hit US$128 billion by 2030
News